GLAXOSMITHKLINE PHARMACEUTICALS
|
GLAXOSMITHKLINE PHARMACEUTICALS Last 5 Year Financial Ratios History
[Consolidated]
| Mar2024 | Mar2023 | Mar2022 | Mar2021 | Mar2020 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 34.83 | 36.05 | 100.04 | 21.14 | 5.50 |
| CEPS(Rs) | 38.94 | 39.75 | 26.50 | 21.60 | 10.38 |
| DPS(Rs) | 32.00 | 32.00 | 90.00 | 30.00 | 40.00 |
| Book NAV/Share(Rs) | 105.47 | 102.89 | 157.19 | 87.26 | 107.47 |
| Tax Rate(%) | 27.72 | 27.35 | 51.12 | 36.72 | 69.52 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 26.31 | 24.73 | 21.20 | 19.14 | 19.55 |
| EBIT Margin(%) | 23.68 | 25.78 | 21.73 | 14.64 | 9.28 |
| Pre Tax Margin(%) | 23.63 | 25.72 | 21.67 | 14.53 | 9.09 |
| PAT Margin (%) | 17.08 | 18.69 | 10.59 | 9.19 | 2.77 |
| Cash Profit Margin (%) | 19.10 | 20.71 | 12.49 | 11.71 | 5.23 |
| Performance Ratios | |||||
| ROA(%) | 17.87 | 15.76 | 10.11 | 9.52 | 1.72 |
| ROE(%) | 33.43 | 27.58 | 18.39 | 17.42 | 4.71 |
| ROCE(%) | 46.49 | 38.06 | 37.72 | 27.74 | 15.76 |
| Asset Turnover(x) | 1.05 | 0.84 | 0.95 | 1.04 | 0.62 |
| Sales/Fixed Asset(x) | 5.25 | 5.31 | 6.03 | 3.04 | 3.34 |
| Working Capital/Sales(x) | 2.71 | 2.78 | 1.79 | 4.68 | 4.47 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 0.19 | 0.19 | 0.17 | 0.33 | 0.30 |
| Receivable days | 21.90 | 22.32 | 21.37 | 18.42 | 11.96 |
| Inventory Days | 52.05 | 55.82 | 54.91 | 60.14 | 52.62 |
| Payable days | 144.03 | 143.05 | 140.69 | 119.53 | 106.45 |
| Valuation Parameters | |||||
| PER(x) | 55.80 | 36.73 | 16.62 | 68.13 | 226.34 |
| PCE(x) | 49.90 | 33.31 | 62.75 | 66.69 | 119.94 |
| Price/Book(x) | 18.42 | 12.87 | 10.58 | 16.51 | 11.59 |
| Yield(%) | 1.65 | 2.42 | 5.41 | 2.08 | 3.21 |
| EV/Net Sales(x) | 9.22 | 6.54 | 7.84 | 7.94 | 6.21 |
| EV/Core EBITDA(x) | 30.89 | 23.51 | 30.67 | 32.80 | 27.18 |
| EV/EBIT(x) | 38.94 | 25.38 | 32.89 | 50.80 | 64.12 |
| EV/CE(x) | 17.92 | 12.22 | 5.68 | 7.72 | 10.99 |
| M Cap / Sales | 9.53 | 6.90 | 8.59 | 8.34 | 6.54 |
| Growth Ratio | |||||
| Net Sales Growth(%) | 6.21 | -0.80 | 12.05 | -9.27 | 3.08 |
| Core EBITDA Growth(%) | 13.96 | 8.03 | 18.19 | -3.74 | 4.71 |
| EBIT Growth(%) | -2.41 | 7.32 | 70.71 | 46.60 | -54.32 |
| PAT Growth(%) | -2.91 | 59.58 | 32.55 | 208.21 | -79.07 |
| EPS Growth(%) | -3.39 | -63.97 | 373.19 | 284.26 | -79.07 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | - | - | - | - | - |
| Current Ratio(x) | 1.84 | 1.88 | 2.18 | 1.49 | 1.74 |
| Quick Ratio(x) | 1.49 | 1.53 | 1.87 | 1.09 | 1.26 |
| Interest Cover(x) | 454.77 | 462.54 | 391.29 | 129.56 | 49.26 |
| Total Debt/Mcap(x) | - | - | - | - | - |
Compare Financial Ratios of peers of GLAXOSMITHKLINE PHARMACEUTICALS
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| GLAXOSMITHKLINE PHARMACEUTICALS | ₹35,408.0 Cr | -6.3% | -9.4% | 4.9% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹418,936.0 Cr | -5.8% | -3.2% | 35.1% | Stock Analytics | |
| DIVIS LABORATORIES | ₹152,157.0 Cr | -2.8% | -3.6% | 44.7% | Stock Analytics | |
| CIPLA | ₹116,200.0 Cr | -3.9% | -0.5% | 13.9% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹111,325.0 Cr | -1.2% | 7.1% | 17.8% | Stock Analytics | |
| ZYDUS LIFESCIENCES | ₹98,037.4 Cr | -2.7% | -0.1% | 40.9% | Stock Analytics | |
GLAXOSMITHKLINE PHARMACEUTICALS Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| GLAXOSMITHKLINE PHARMACEUTICALS | -6.3% |
-9.4% |
4.9% |
| SENSEX | -2.1% |
-6.4% |
7% |
You may also like the below Video Courses
